Rtw Investments Lp
- Regulatory AUM
- $14.1B
- Discretionary
- $14.1B
- Clients
- 10
- Avg AUM / client
- $1.4B
- Accounts
- 10
- Employees
- 70
AUM over time
Annual snapshots from Form ADV filings · as of Mar 30, 2026
Investments (13F portfolio — 88 positions, $10,049,752,600)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Madrigal Pharmaceuticals Inc | COM | $1,043,635,334 | 1,993,687 | 10.4% | 7.38% |
| 2 | Insmed Inc | COM PAR $.01 | $791,907,738 | 4,842,880 | 7.88% | 5.6% |
| 3 | Protagonist Therapeutics Inc | COM | $533,224,186 | 5,059,053 | 5.31% | 3.77% |
| 4 | Ptc Therapeutics Inc | COM | $527,763,254 | 7,746,415 | 5.25% | 3.73% |
| 5 | Argenx Se | SPONSORED ADR | $518,072,942 | 709,446 | 5.16% | 3.66% |
| 6 | Cg Oncology Inc | COM | $472,731,805 | 6,984,808 | 4.7% | 3.34% |
| 7 | Celcuity Inc | COM | $346,942,341 | 3,039,621 | 3.45% | 2.45% |
| 8 | Tango Therapeutics Inc | COM | $278,248,970 | 13,300,620 | 2.77% | 1.97% |
| 9 | Erasca Inc | COM | $261,423,092 | 16,157,175 | 2.6% | 1.85% |
| 10 | Natera Inc | COM | $249,987,500 | 1,250,000 | 2.49% | 1.77% |
| 11 | Radnet Inc | COM | $239,488,650 | 4,285,000 | 2.38% | 1.69% |
| 12 | Tarsus Pharmaceuticals Inc | COM | $234,723,654 | 3,346,025 | 2.34% | 1.66% |
| 13 | Apogee Therapeutics Inc | COM | $234,169,104 | 2,782,097 | 2.33% | 1.66% |
| 14 | Spyre Therapeutics Inc | COM NEW | $210,435,478 | 4,171,996 | 2.09% | 1.49% |
| 15 | Cogent Biosciences Inc | COM | $210,104,401 | 5,458,675 | 2.09% | 1.49% |
| 16 | Irhythm Holdings Inc | COM | $196,916,370 | 1,668,500 | 1.96% | 1.39% |
| 17 | Stoke Therapeutics Inc | COM | $183,101,974 | 5,623,525 | 1.82% | 1.3% |
| 18 | Cytokinetics Inc | COM NEW | $179,351,524 | 2,721,158 | 1.78% | 1.27% |
| 19 | Acadia Pharmaceuticals Inc | COM | $159,037,104 | 7,144,524 | 1.58% | 1.12% |
| 20 | Establishment Labs Hldgs Inc | COM | $150,790,362 | 2,655,695 | 1.5% | 1.07% |
| 21 | Apellis Pharmaceuticals Inc | COM | $148,249,360 | 3,685,045 | 1.48% | 1.05% |
| 22 | Immunocore Hldgs Plc | ADS | $146,824,410 | 4,869,798 | 1.46% | 1.04% |
| 23 | Repligen Corp | COM | $142,090,920 | 1,206,000 | 1.41% | 1.01% |
| 24 | Neurocrine Biosciences Inc | COM | $139,917,365 | 1,062,072 | 1.39% | 0.99% |
| 25 | Guardant Health Inc | COM | $136,803,018 | 1,481,033 | 1.36% | 0.97% |
Top 25 of 88 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 10 | $14.1B | 100.0% |
Private funds (3)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $8.4B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Rtw Master Fund, Ltd. master | Hedge Fund | Cayman Islands | $5.1B | 1,418 |
| Rtw Innovation Master Fund, Ltd. master | Hedge Fund | Cayman Islands | $3.3B | 349 |
| 4010 Royalty Investments Icav master | Private Equity Fund | Ireland | $81.1M | 35 |
People (9)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Wong, Roderick, Tze Ian | Managing Partner, Chief Investment Officer | Sep 2009 (17y) | 75% or more | |
| Loughran, Sabera, Reza | Partner Emeritus | Oct 2009 (17y) | Less than 5% | |
| Sirota, Stephanie, Anne | Partner, Chief Business Officer | Jan 2014 (13y) | Less than 5% | |
| Yalamanchi, Naveen | Partner, Portfolio Manager | Jan 2016 (11y) | 10% – 25% | |
| Aurigema, Robert, John | Partner, Chief Operating Officer And Chief Financial Officer | Aug 2020 (6y) | Less than 5% | |
| Patel, Darshan, Vishnu | Chief Compliance Officer | Feb 2021 (6y) | Less than 5% | |
| Seiter, Christopher, John | Chief Corporate Finance Officer | Apr 2021 (5y) | Less than 5% | |
| Fong, Peter, M | Partner, President | Jan 2022 (5y) | Less than 5% | |
| Makker, Gotam | Partner, Head Of Strategic Investments | Sep 2023 (3y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Rtw Investments Gp, Llc | General Partner Of Rtw Investments, Lp | Apr 2016 | A | Less than 5% |
Undisclosed: 0% – 15% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (3, $8.4B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Rtw Master Fund, Ltd. | Hedge Fund | $5.1B | $10.0M | 1,418 |
| Rtw Innovation Master Fund, Ltd. | Hedge Fund | $3.3B | $10.0M | 349 |
| 4010 Royalty Investments Icav | Private Equity Fund | $81.1M | $100K | 35 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/30/2026 | 2.36 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
Allegations: ON MAY 30, 2023, THE SEC ISSUED AN ORDER FINDING THAT RTW (1) FAILED TO DISCLOSE CERTAIN CONFLICTS OF INTEREST REGARDING ITS PERSONNEL'S CO-INVESTMENT WITH THE FUNDS IN THE SPONSORS OF SPACS IN WHICH RTW ADVISED FUNDS TO INVEST AND (2) FAILED TO TIMELY FILE ACCURATE REPORTS ON SCHEDULE 13G CONCERNING BENEFICIAL OWNERSHIP OF STOCK IN A PUBLIC COMPANY. RTW CONSENTED TO THE ENTRY OF THE SEC'S ORDER FINDING THAT IT VIOLATED SECTIONS 206(2) AND 206(4) OF THE INVESTMENT ADVISERS ACT OF 1940 AND RULES 206(4)-7 AND 206(4)-8, AS WELL AS SECTION 13(D) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULES 13D-1 AND 13D-2. WITHOUT ADMITTING OR DENYING THE FINDINGS, RTW AGREED TO A CEASE-AND-DESIST ORDER, A CENSURE, AND A $1.4 MILLION PENALTY TO SETTLE THE CHARGES. Status: Final Sanction Detail: THE APPLICANT CONSENTED TO THE SEC'S ORDER FINDING IT VIOLATED SECTIONS 206(2) AND 206(4) OF THE INVESTMENT ADVISERS ACT OF 1940 AND RULES 206(4)-7 AND 206(4)-8, AS WELL AS SECTION 13(D) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULES 13D-1 AND 13D-2. WITHOUT ADMITTING OR DENYING THE FINDINGS THE APPLICANT AGREED TO A CEASE-AND-DESIST ORDER, A CENSURE AND $1.4 MILLION PENALTY PAID ON JUNE 1, 2023 TO SETTLE THE CHARGES. Summary: THE SEC MATTER WAS SETTLED ON MAY 30, 2023 PURSUANT TO THE ORDER DESCRIBED ABOVE.
Disclosure text reproduced verbatim from the firm's own Form ADV filings.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 30, 2026.
View current Form ADV (SEC/IAPD) ↗